Table 2.
Cohort response to pembrolizumab.
| Patient ID | Response to treatment | |||||||
|---|---|---|---|---|---|---|---|---|
| No of blood samples | Cycle no. at start of blood collection | Pembrolizumab cycle range | Response | After cycle | Type | Progressive disease | Responder/ Non-responder | |
| 173 | 11 | 3 | 3–19 | PR | 4 | Metabolic | No | R |
| 205 | 13 | 20 | 20–33 | PR/CR | 4/22 | RECIST | No | R |
| 206 | 13 | 23 | 23–39 | PR | 4 | iRECIST | Yes | NR |
| 209 | 10 | 18 | 18–30 | CR | 4 | RECIST | No | R |
| 213 | 11 | 6 | 6–16 | CR | 4 | Metabolic | No | R |
| 216 | 12 | 20 | 20–31 | CR | 8 | Metabolic | No | R |
| 218 | 11 | 6 | 6–17 | PR | 4 | RECIST | No | R |
| 219 | 10 | 26 | 26–38 | PR | 4 | iRECIST | Yes | NR |
| 220 | 4 | 2 | 2–5 | PD | 4 | iRECIST | Yes | NR |
| 254 | 11 | 2 | 2–13 | SD | na | RECIST | No | R |
| 257 | 1 | 18 | 18 | PD | na | iRECIST | Yes | NR |
| 259 | 4 | 20 | 20–23 | CR | 4 | RECIST | No | R |
| 266 | 7 | 5 | 5–11 | CR | 4 | Metabolic | No | R |
| 295 | 7 | 1 | 1–8 | CR | 11 | RECIST | No | R |
| 318 | 5 | 11 | 11–15 | PR | 4 | RECIST | No | R |
| 333 | 2 | 1 | 1–2 | PD | 1 | iRECIST | Yes | NR |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors, iRECIST, immune RECIST; Metabolic, response determined by LDH levels: R, responder; NR, non-responder.